Lupin to market and sell Lilly's rapid action insulin analog Lispro Eglucent
Lupin and Eli Lilly and Company (India) announced an expansion of their partnership in India with the launch of Eglucent, a new brand of Lilly's rapid action insulin analog Lispro.According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
